KR20130102177A - The ginseng polysaccaride hydrolysates with inhivition of helicobacter pylori-cell adhesion and a composition for preventing or treating gastrointestinal disease - Google Patents

Abstract

PURPOSE: A ginseng polysaccharide hydrolysate is provided to suppress Helicobacter pylori-cell adhesion. CONSTITUTION: A composition for preventing and treating gastrointestinal diseases contains hydrolysates with enhanced suppression of hemagglutination by Helicobacter pylori. The hydrolysates are prepared by treating ginseng polysaccharides with glycolytic enzyme. Hydrolase is selected among alpha-amylase, amyloglucosidase, alpha-glucosidase, beta-glucosidase, cellulase, and pectinase. The enzyme used in polysaccharide hydrolysis is alpha-amylase. [Reference numerals] (AA) Ginseng root (pulverizing); (BB) Extracting with water; (CC,FF,II) Precipitate; (DD,GG,JJ) Supernatant; (EE) Concentrating, adding ethanol; (HH) Enzyme processing; (KK) Enzyme hydrolysate

Description

The ginseng polysaccaride hydrolysates with inhivition of Helicobacter pylori-cell adhesion and a composition for preventing or treating gastrointestinal disease}

The present invention relates to a ginseng polysaccharide hydrolyzate and a composition for preventing and treating digestive diseases containing the same as an active ingredient. More specifically, the present invention relates to a composition for preventing and treating gastrointestinal diseases, which contains a polysaccharide hydrolyzate isolated from ginseng root that inhibits gastric mucosal cell binding of Helicobacter pylori, which is known as a causative agent of gastrointestinal diseases.

Helicobacter pylori is a Gram-negative bacterium that causes chronic active gastritis and gastroduodenal ulcers and is recognized as an important factor in gastric cancer and gastric mucosal lymphoid tissue. In 1994, the World Health Organization (WHO) defined H. pylori as the primary carcinogen of gastric cancer, and the importance of H. pylori became more important and the pathogenesis of H. pylori pathological diseases was Much research is being done to find out.

In developed countries, the infection rate is relatively lower than that in developing and developing countries. However, the infection rate is higher than 60% and should not be overlooked. Furthermore, given the main paths of infection, such as oral to oral and fecal to oral, environmental factors have a significant impact on the infection, so if any family member has an adult, the children of the family have a high infection rate, so they It is reported that this increases the risk of developing gastric ulcer or gastric cancer.

Previously, gastrointestinal diseases such as gastritis and gastric ulcers were known to be primarily caused by excessive gastric acid secretion, which is caused by stress, food, and genetic factors, but recently, when infected with H. pylori It is hypothesized that inflammation of the stomach occurs. When inflammation spreads to the submucosa of the stomach, it develops into gastric ulcers. And although this does not immediately lead to gastric cancer, it is known that infection with H. pylori increases the risk of developing gastric cancer by 3-5 times.

The essential process for H. pylori to cause gastrointestinal lesions is the side effect (or adhesion) that occurs between H. pylori and gastrointestinal epithelial cells. It has been reported previously that H. pylori binds to gastrointestinal mucosal epithelial cells, the binding mechanism of which is mainly dependent on the interaction between carbohydrates and bacterial surface proteins that recognize it. Examples of the recognized carbohydrates include sulfated carbohydrates of mucin glycoproteins, sialyllactose and fucosylated Lewis b antigens. Recently, efforts have been made to inhibit bacterial cell binding using glycosphingolipids or mucin proteins in saliva. The isolation and identification of bacterial surface protein receptors (adhesin) has already been made, and the development of glycopolymers using recognized carbohydrates is a very important subject.

The surface of red blood cells, which have been used for cell-to-cell recognition, possesses the same or similar carbohydrate composition as gastric mucosal epithelial cells and causes aggregation by binding to Helicobacter. Most bacterial cells show agglutination, which occurs when the binding protein on the bacterial surface recognizes carbohydrates on the surface of host cells such as red blood cells.

Antagonists and histamine antagonists have been used to treat gastrointestinal diseases many years ago. The National Institutes of Health recognized the relationship between Helicobacter and gastrointestinal diseases only in the mid-90s. The use of antibiotics such as or amoxicillin was allowed to be used in combination with other therapeutic agents.

However, due to the use of antibiotics in the body of antibiotics accumulate and side effects, as well as the use of these cells and cell destruction and the emergence of antibiotic-resistant bacteria, the need for the development of alternative drugs that can eventually treat gastrointestinal diseases is emerging. As a result, the development of domestic and foreign gastrointestinal disease treatment and preventive agents has been the mainstream in the production of kits using immune system or antimicrobial agent or bacterial extracellular excretion enzyme. There is no development of a drug using a glycomer involved in cell recognition.

On the other hand, ginseng is one of the drugs that have been used in Oriental medicine is very effective. Panax ginseng includes Panax ginseng, Panax quinquefolius, and Eleutherococcus senticosus. In general, Korean ginseng produced in Korea is known to have the best effect. Ginseng has long been used to save lives in emergencies, and has been used as a tonic, energetic, stimulant and anti-aging agent, and improves the health of the body to activate nonspecific immune responses that resist various infections and diseases. It is also used as an 'adaptogen'. Recently, many efforts have been made to investigate the utility of ginseng from the modern medical point of view, and the effects on the central nervous system, the cardiovascular system, the endocrine system and the immune system have been revealed.

Meanwhile, conventional techniques related to inhibition of H. pylori cell binding of ginseng include acidic polysaccharide fractions isolated from ginseng roots that inhibit cell binding of H. pylori and a method of preparing the same (Public Patent Publication 10-0330138). . The acidic polysaccharide fraction separated from the water-soluble extract of Panax ginseng by ion exchange chromatography has a higher content of uronic acid than other polysaccharide fractions and inhibits hemagglutination by Helicobacter. Due to the relatively high activity, isolated acidic polysaccharide fractions have been disclosed for use as a preventive and therapeutic agent for gastrointestinal diseases caused by H. pylori.

As such, conventionally, biological activity measurement using fractions obtained by separating and purifying acidic polysaccharides from crude extracts containing ginseng polysaccharides or carbohydrates through ion exchange chromatography has been performed. However, the method has a disadvantage that it takes time and cost to use industrially. Therefore, the present inventors, while studying the inhibitor of H. pylori cell binding, confirmed that the polysaccharide hydrolyzate isolated from the ginseng root has a strong inhibitory effect on the hemagglutination reaction of H. pylori, which is a high preventive agent for preventing and treating gastrointestinal diseases. The possibilities have been demonstrated to complete the present invention.

Accordingly, it is an object of the present invention to provide a ginseng hydrolyzate having a cell binding inhibitory activity of H. pylori.

Another object of the present invention to provide a method for producing a ginseng hydrolyzate having a cell binding inhibitory activity of the H. pylori.

An object of the present invention is to prepare a composition for the prevention and treatment of gastrointestinal diseases by the hydrolyzate obtained by treating the polysaccharide obtained from the water-soluble extract of ginseng with an enzyme shows a significant improvement in H. pylori hemagglutination inhibitory activity than the polysaccharide before hydrolysis. To provide a method.

The present invention for achieving the above object is a step of obtaining a polysaccharide fraction by ethanol treatment after extracting the ginseng root distilled water, hydrolysis of H. pylori hemagglutination, characterized in that it comprises the step of hydrolyzing the glycolysis enzyme in the fraction It provides a method for producing a composition for preventing and treating gastrointestinal diseases with activity.

The present invention can provide a method for producing a ginseng polysaccharide hydrolyzate that inhibits the Helicobacter erythrocyte aggregation reaction by hydrolyzing the ginseng polysaccharide. Ginseng polysaccharide hydrolyzate according to the present invention is a composition for preventing and treating gastrointestinal diseases by inhibiting gastric intestinal intestinal cell binding of Helicobacter.

BRIEF DESCRIPTION OF THE DRAWINGS The figure explaining the method of obtaining polysaccharide hydrolyzate from ginseng.
Figure 2 is a micrograph of H. pylori hemagglutination inhibitory activity of the polysaccharide hydrolysates of four glycolysis
3 is a micrograph of H. pylori hemagglutination inhibitory activity according to the reaction time of α-amylase enzyme hydrolyzate
4 is a micrograph of H. pylori hemagglutination inhibitory activity according to the concentration of α-amylase enzyme hydrolyzate

In order to achieve the object of the present invention, the present invention is a polysaccharide obtained by pulverizing the ginseng root, hot water extraction and then ethanol precipitation, the cell of H. pylori characterized by a substance obtained by hydrolyzing the ethanol precipitate with an enzyme It provides a polysaccharide hydrolyzate having binding inhibitory activity.

Due to the cell binding inhibitory activity of the Helicobacter of the present invention, H. pylori is effective in the prevention and treatment of various digestive diseases (ie, gastrointestinal diseases) caused by binding to gastric mucosal epithelial cells, such as gastritis, gastric ulcer, and gastric cancer. I understand.

In the polysaccharide hydrolyzate of the present invention, the hydrolyzate is preferably a hydrolyzate using glycolysis α-amylase. The hydrolyzate showed excellent cell binding inhibitory activity of H. pylori.

In order to achieve the other object of the present invention, the present invention (1) pulverizing ginseng root and extracted with distilled water at 60 ~ 100 ℃ and centrifugation of the supernatant obtained by concentration under reduced pressure to 5 ~ 20 brix to obtain a ginseng water-soluble extract ; (2) adding ethanol 1.5-7 times to the concentrate of step (1) to immerse and centrifuge to obtain an ethanol precipitate; (3) dissolving the precipitate of step (2) in distilled water to obtain a hydrolyzate by treating 0.1-2% of the enzyme; (4) provides a method for producing a ginseng polysaccharide hydrolyzate comprising the step of lyophilizing the hydrolyzate obtained in step (3) to obtain a polysaccharide hydrolyzate.

In order to achieve another object of the present invention, the present invention provides a composition for the prevention and treatment of gastrointestinal diseases, such as gastritis, gastric ulcer or gastric cancer, containing the polysaccharide hydrolyzate according to the invention as an active ingredient.

The composition for preventing or treating gastrointestinal diseases may include the polysaccharide hydrolyzate alone as an active ingredient, and additional ingredients, pharmaceutically acceptable or nutritionally acceptable carriers, depending on the formulation, method of use, and purpose of use. It may further comprise excipients, diluents or subcomponents.

More specifically, the composition for preventing or treating gastrointestinal diseases may further include nutrients, vitamins, electrolytes, flavors, colorants, neutralizers, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners in addition to the active ingredient. , pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. In addition, the carrier, excipient or diluent may be lactose, dextrose, sucrose, sorbitol, mannitol, ziitol, erythritol, maltitol, starch, acycia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline Group consisting of cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, dextrin, calcium carbonate, propylene glycol, liquid paraffin, physiological saline It may be one or more selected from, but is not limited to any conventional carriers, excipients or diluents can be used. The components may be added independently or in combination with the polysaccharide hydrolyzate which is the active ingredient.

In addition, the composition for preventing or treating gastrointestinal diseases may further include conventional fillers, extenders, binders, disintegrants, surfactants, anti-coagulants, lubricants, wetting agents, fragrances, emulsifiers or preservatives, It can be used orally or parenterally.

Specifically, the solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and the solid preparations include at least one excipient such as starch, calcium carbonate, calcium carbonate, It is prepared by mixing sucrose or lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral use include suspensions, solvents, emulsions, and syrups.In addition to the commonly used simple diluents, water and liquid paraffin, various excipients may include, for example, wetting agents, sweeteners, fragrances, and preservatives. have.

In addition, the formulation of the composition for the prevention or treatment of gastrointestinal diseases of the present invention may be in a preferred form depending on the method of use, and is known in the art to provide rapid, sustained or delayed release of the active ingredient, especially after administration to a mammal. Formulation may be adopted by formulating. Examples of specific formulations include granules, powders, syrups, solutions, suspensions, tablets, injections, spirits, cataplasma, capsules, soft or hard gelatin capsules, and the like.

Further, compositions for preventing or treating gastrointestinal diseases of the present invention can be prepared using methods known in the art or as disclosed in Remington's Pharmaceutical Science (Recent), Mack Publishing Company, Easton PA. And preferably formulated.

In addition, the present invention provides a food composition for preventing or improving gastrointestinal diseases, including the polysaccharide hydrolyzate as an active ingredient.

In the present specification, the term "food" means a natural product or processed product containing one or more nutrients, and preferably means a state in which it can be directly eaten through some processing process. It is intended to include all dietary supplements, beverages, food additives and beverage additives.

Examples of the food of the present invention include various foods, beverages, gums, teas, vitamin complexes, and health functional foods. In addition, the food in the present invention includes special nutritional products (e.g., prepared oils, infants, baby food, etc.), processed meat products, fish products, tofu, jelly, noodles (e.g. ramen, noodles, etc.), health supplements, seasoned foods ( For example, soy sauce, miso, red pepper paste, mixed soy sauce), sauces, confectionery (e.g. snacks), dairy products (e.g. fermented milk, cheese, etc.), other processed foods, kimchi, pickles (various kimchi, pickles, etc.), beverages ( Examples include, but are not limited to, fruits, vegetable drinks, soy milk, fermented beverages, and the like, and natural seasonings (eg, ramen soup). The food, health functional food, beverages, food additives and beverage additives may be prepared by conventional manufacturing methods.

In the present invention, a health functional food is a biological defense rhythm control, disease prevention and the like having a food group or a food composition which has added value to the food by using physical, biochemical, biotechnological techniques, etc. It means a food that is designed and processed to fully express the gymnastics function on recovery.

The dietary supplement may include food acceptable food additives, and may further include appropriate carriers, excipients and diluents commonly used in the manufacture of dietary supplements.

In the present invention, the drink refers to a generic term for drinking to quench thirst or to enjoy the taste and is intended to include a functional beverage. The beverage is not particularly limited to other ingredients other than including the polysaccharide hydrolyzate as an active ingredient as an essential ingredient at the indicated ratio, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. have.

Examples of such natural carbohydrates include monosaccharides such as glucose, fructose and other disaccharides such as maltose, sucrose and the like and polysaccharides such as dextrin, cyclodextrin and the like, and Sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The ratio of the natural carbohydrate may generally be about 1 to 20 g, preferably 5 to 12 g per 100 ml of the food composition of the present invention, in addition to the composition of the present invention for the production of natural fruit juices, fruit juice drinks, vegetable drinks It may further contain pulp for.

In addition to the above, the food composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese, chocolate), pectic acid and salts thereof, alginic acid and Salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages and the like. These components can be used independently or in combination. The proportion of such additives is not so critical, but may be selected in the range of 0 to 20 parts by weight per 100 parts by weight of the polysaccharide hydrolyzate of the present invention.

In the present invention, the health functional beverage is a biological defense rhythm control or disease prevention of a beverage group or beverage composition which has added value to the beverage by using physical, biochemical and biotechnological techniques to act and express the function of the beverage for a specific purpose. Means a beverage that is designed and processed to fully express the gymnastic function related to recovery and the like.

The health functional beverage is not particularly limited to other ingredients except the polysaccharide hydrolyzate of the present invention as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. .

Examples of such natural carbohydrates include monosaccharides such as glucose, fructose and other disaccharides such as maltose, sucrose and the like and polysaccharides such as dextrin, cyclodextrin and the like, and xylitol Sugar alcohols such as sorbitol and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of natural carbohydrates is generally about 1 to 20 g, preferably 5 to 12 g per 100 ml of the composition of the present invention.

In addition, in the food composition for the purpose of preventing or improving gastrointestinal diseases, the amount of the polysaccharide hydrolyzate may include 0.01 to 15% by weight of the total food weight, the beverage composition is based on 100 ml 0.02 to 5g, preferably 0.3 to 1g.

Hereinafter, the present invention will be described in detail.

The present invention consists of a method for preparing ginseng polysaccharide hydrolyzate that inhibits erythrocyte aggregation reaction caused by H. pylori, a major pathogen of gastrointestinal diseases. First, for the polysaccharide fraction, it is extracted with hot distilled water according to the general intake and extraction method of ginseng. This is in contrast to the conventional extraction method of natural bioactive substances using organic solvents, which are difficult to apply mainly to foods and drugs, and can be said to be a more practical approach and human-friendly for the search for bioactive substances. 2) The hydrolyzed polysaccharides showed slightly lower inhibitory activity of H. pylori gastric epithelial cell adhesion of acidic polysaccharides of ginseng, green tea, and mugwort than previously reported, but separation processes such as ion exchange and gel filtration chromatography to obtain acidic polysaccharides. In the sense that this is not necessary, the industrial use value is high. Therefore, the technical problem to be achieved by the present invention is to extract the ginseng root with distilled water, without the separation process such as ion exchange and gel filtration chromatography to separate the active polysaccharide acid polysaccharide, using a simple water It is composed of the step of obtaining polysaccharide hydrolyzate through the decomposition process and the activity measurement step of inhibiting hemagglutination by H. pylori.

Enzyme alpha-amylase, amyloglucosidase, alpha-glucosidase, beta-glucosidase, cellulase used in the present invention , Pectinase and the like were purchased from Sigma, USA.

Type O erythrocytes required for erythrocyte agglutination reaction used in the present invention was obtained from Hallym University Health Center, and used after treatment with anticoagulant. More specifically, the collected blood was centrifuged at 300 xg for 10 minutes at 4 ° C to remove plasma, and the precipitated erythrocytes were suspended with 0.1M phosphate buffer solution containing EDTA, gently stirred, washed and centrifuged as described above. The supernatant was removed. The above procedure was repeated until the supernatant became clear to prevent incorporation of white blood cells.

The Helicobacter bacterium (ATCC 43504) used in the present invention was used in two passages at 37 ° C. and 10% CO ₂ in brucella broth containing 10% fetal bovin serum and antibiotics (cefsulodin, vancomycin, trimethoprim). It was.

Ginseng used in the present invention was used commercially available.

When the degree of inhibition of erythrocyte aggregation reaction of the ginseng polysaccharide hydrolyzate used in the present invention was measured, the α-amylase hydrolyzate showed a inhibitory activity at a low concentration of 1.66 mg / mL. When preparing a product for the prevention and treatment of gastrointestinal diseases, the final concentration of the polysaccharide hydrolyzate of the present invention is preferably added in an amount of 1.66mg / mL or more.

Hereinafter, the present invention will be described in detail by way of Examples, but the scope of the present invention is not limited to these Examples.

Preparation Example 1 Preparation of Polysaccharide Fraction from Ginseng Root

As already reported, the ginseng polysaccharide manufacturing method is pulverized 1kg ginseng root, extracted with 10 L of distilled water at 80-100 ° C. in a vessel equipped with a reflux device, filtered and concentrated under reduced pressure to concentrate the extract to 8-10 brix. After adjusting, the precipitate obtained by adding 2 times the volume of ethanol was lyophilized. The ginseng polysaccharide extract obtained was 36.5 g.

Examples 1 to 6: Preparation of hydrolyzate of polysaccharide according to enzyme

100 mL of distilled water was added to 1 g of the polysaccharide precipitate of Preparation Example 1, and α-amylase, amyloglucosidase, α-glucosidase, β-glucosidase, cellulase, and pectinase were added at a concentration of 0.2% (w / w) for 6 hours at 50 ° C. After the reaction, the mixture was left in boiling water at 100 ° C. for 5 minutes to inactivate the enzyme, followed by centrifugation (4,000 rpm, 4 ° C., 20 minutes) to remove the precipitate, and the obtained supernatant was lyophilized.

Examples 7 to 10: Preparation of hydrolyzate according to enzyme concentration

100 mL of distilled water was added to 1 g of the polysaccharide precipitate of Preparation Example 1, and the α-amylase enzyme was added at various concentrations of 0.02% to 2% (w / w) and reacted at 50 ° C for 6 hours, followed by boiling water at 100 ° C. After standing for 5 minutes to inactivate the enzyme and centrifuged (4,000rpm, 4 ℃, 20 minutes) to remove the precipitate and the obtained supernatant was lyophilized.

Examples 11 to 15 Preparation of hydrolyzate according to temperature

100 mL of distilled water was added to 1 g of the polysaccharide precipitate of Preparation Example 1, and α-amylase was added at a concentration of 0.2% (w / w) to react for 6 hours at various temperature conditions from 30 ° C. to 70 ° C., followed by boiling at 100 ° C. After standing in water for 5 minutes to inactivate the enzyme and centrifuged (4,000rpm, 4 ℃, 20 minutes) to remove the precipitate and the supernatant obtained was lyophilized.

Examples 16-20: Preparation of Hydrolysates Over Time

100 mL of distilled water was added to 1 g of the polysaccharide precipitate of Preparation Example 1, and α-amylase was added at a concentration of 0.2% (w / w) and reacted at 50 ° C. for 1, 3, 6, 9 and 24 hours, followed by 100 ° C. Incubated for 5 minutes in boiling water to inactivate the enzyme and centrifuged (4,000rpm, 4 ℃, 20 minutes) to remove the precipitate and the obtained supernatant was lyophilized.

Experimental Example 1 Inhibition of Hemagglutination by H. pylori

The cultured H. pylori was diluted with 0.1 M phosphate buffer (pH 7.3), mixed with an equal amount of red blood cell solution, and stirred for 1 to 2 hours at room temperature to react with positive red blood cell aggregation (PC). Erythrocyte dilution without pylori was used as a negative hemagglutination (NC) reaction. In order to inhibit the agglutination reaction of the polysaccharide hydrolyzate, the H. pylori suspension and the polysaccharide hydrolyzate were mixed, reacted at room temperature for 30 minutes, and then reacted by mixing the red blood cell diluent again. It was.

Inhibitory Activity of Hemagglutination by H. pylori under Different Hydrolysis Conditions division Minimum inhibitory activity concentration (mg / mL) Production Example 1 Ginseng Polysaccharide 16.6 Example 1 α-amylase treatment group 1.66 Example 2 amyloglucosidase treatment group No inhibitory activity at 3.33 Example 3 α-glucosidase treatment group No inhibitory activity at 3.33 Example 4 β-glucosidase treatment group No inhibitory activity at 3.33 Example 5 cellulase treatment group No inhibitory activity at 3.33 Example 6 pectimase treatment group 3.33 Example 7 0.02% treatment group 3.33 Example 8 0.2% treatment group 1.66 Example 9 1% treatment group 2.49 Example 10 2% treatment group 3.33 Example 11 30 ℃ reaction No inhibitory activity at 3.33 Example 12 40 ℃ reaction 2.49 Example 13 50 ℃ reaction 1.66 Example 14 60 ℃ reaction 3.33 Example 15 70 ℃ reaction No inhibitory activity at 3.33 Example 16 1 hour response 2.49 Example 17 3 hours response 1.66 Example 18 6 hours reaction 1.66 Example 19 9 hours response 3.33 Example 20 24 hour reaction 3.33

As shown in Table 1, as a result of measuring the hemagglutination inhibition activity of H. pylori by the ginseng polysaccharide hydrolyzate according to the conditions, the ginseng polysaccharide extract (Preparation Example 1) did not show the inhibitory activity even at a high concentration of 3.3 mg / mL. However, among the hydrolyzates treated with six glycolytic enzymes (α-amylase, amyloglucosidase, α-glucosidase, β-glucosidase, cellulase, pectinase), the α-amylase enzyme treatment group showed relatively high inhibitory activity (Fig. 2). . Therefore, the hydrolyzate treated with α-amylase enzyme by concentration showed relatively good inhibitory activity in the treated group of 0.2% and 1%, the reaction temperature was 50 ℃, and the inhibitory activity with time was 3 hours after enzyme treatment. It was confirmed that a relatively good inhibitory activity appeared at 6 hours (Fig. 3).

Ginseng polysaccharide hydrolysis conditions through the above Example was treated with 0.2 ~ 1% α-amylase enzyme, the temperature is 40 ~ 50 ℃, the reaction time was confirmed as the optimum conditions within 3 to 6 hours. The hydrolyzate under these conditions showed inhibitory activity in a concentration-dependent manner, and the inhibitory activity was found even at a low concentration of 1.66 mg / mL compared to the positive erythrocyte aggregation reaction (FIG. 4).

Claims (5)

A composition for preventing and treating gastrointestinal diseases, wherein the ginseng polysaccharide contains a hydrolyzate having enhanced inhibitory activity against erythrocyte aggregation by H. pylori, which comprises the step of treating glycolytic enzymes. The method according to claim 1, wherein the hydrolase is at least one selected from alpha-amylase, amyloglucosidase, alpha-glucosidase, beta-glucosidase, cellulase, and pectinase. Method for producing hydrolyzate with enhanced hemagglutination inhibitory activity The method of claim 1, wherein the enzyme used for hydrolysis of the polysaccharide is alpha-amylase. The method of claim 1, wherein the enzyme alpha-amylase used in the hydrolysis of polysaccharide is added to 0.01 to 2%.
The method of claim 1, wherein the alpha-amylase enzyme-treated polysaccharide reacts for 1 to 24 hours at 30 to 60 ° C.

Images